<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ozempic vs Mounjaro: Which Is Better for Weight Loss?</title>
    <meta name="description" content="Head-to-head comparison of Ozempic vs Mounjaro for weight loss and diabetes. Compare clinical data, cost, side effects, and mechanisms (GLP-1 vs dual GIP/GLP-1).">
    <link rel="canonical" href="https://ozempic.md/ozempic-vs-mounjaro">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://ozempic.md/ozempic-vs-mounjaro">
    <meta property="og:title" content="Ozempic vs Mounjaro: Which Is Better for Weight Loss?">
    <meta property="og:description" content="Head-to-head comparison of Ozempic (semaglutide) vs Mounjaro (tirzepatide) — clinical data, cost, side effects, and mechanism differences.">
    <meta property="og:site_name" content="ozempic.md">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="ai-content" content="allowed">
    <meta name="ai-topic" content="ozempic vs mounjaro, semaglutide vs tirzepatide, GLP-1 comparison, weight loss medications">

    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "MedicalWebPage",
          "@id": "https://ozempic.md/ozempic-vs-mounjaro#webpage",
          "name": "Ozempic vs Mounjaro: Which Is Better for Weight Loss?",
          "description": "Evidence-based comparison of Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight loss and type 2 diabetes management.",
          "url": "https://ozempic.md/ozempic-vs-mounjaro",
          "isPartOf": {"@id": "https://ozempic.md/#website"},
          "lastReviewed": "2026-02-01",
          "reviewedBy": {"@type": "Person", "name": "Dr. Agustin Arrieta", "jobTitle": "MD"}
        },
        {
          "@type": "FAQPage",
          "@id": "https://ozempic.md/ozempic-vs-mounjaro#faq",
          "mainEntity": [
            {
              "@type": "Question",
              "name": "Is Mounjaro better than Ozempic for weight loss?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Clinical trials suggest Mounjaro (tirzepatide) produces greater weight loss than Ozempic (semaglutide). In the SURPASS-2 trial, tirzepatide at its highest dose (15 mg) produced average weight loss of 25+ pounds vs ~12-14 pounds with semaglutide 1 mg in SUSTAIN trials. However, direct head-to-head data is limited, and individual responses vary."
              }
            },
            {
              "@type": "Question",
              "name": "What is the difference between Ozempic and Mounjaro?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "The key difference is mechanism: Ozempic (semaglutide) targets only the GLP-1 receptor, while Mounjaro (tirzepatide) targets both GLP-1 and GIP receptors (dual agonist). Both are once-weekly injections for type 2 diabetes. Mounjaro's dual mechanism appears to produce greater A1C reduction and weight loss in clinical trials."
              }
            },
            {
              "@type": "Question",
              "name": "Which has fewer side effects, Ozempic or Mounjaro?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Both medications have similar GI side effect profiles (nausea, vomiting, diarrhea). In clinical trials, nausea rates were comparable: ~15-20% for Ozempic and ~12-18% for Mounjaro depending on dose. Discontinuation rates due to side effects were similar at ~4-7% for both drugs."
              }
            },
            {
              "@type": "Question",
              "name": "Is Ozempic or Mounjaro cheaper?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Both are similarly priced without insurance: Ozempic costs approximately $900-$1,000/month and Mounjaro costs approximately $1,000-$1,100/month at retail. Both manufacturers offer savings programs for eligible commercially insured patients. Actual out-of-pocket cost depends heavily on your insurance plan's formulary."
              }
            },
            {
              "@type": "Question",
              "name": "Can I switch from Ozempic to Mounjaro?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Yes, switching is possible under medical supervision. Your doctor will determine the appropriate starting dose of Mounjaro based on your current Ozempic dose. There is no required washout period. Some patients switch because they've plateaued on Ozempic or want to try the dual-agonist approach for greater weight loss."
              }
            },
            {
              "@type": "Question",
              "name": "Does Mounjaro have a cardiovascular benefit like Ozempic?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Ozempic has demonstrated cardiovascular benefit in the SUSTAIN 6 trial (26% reduction in MACE). Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with preliminary results expected in 2026. Tirzepatide does not yet have an FDA-approved cardiovascular indication."
              }
            }
          ]
        }
      ]
    }
    </script>

    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root { --bg-primary: #ffffff; --bg-secondary: #f8fafc; --bg-tertiary: #f1f5f9; --text-primary: #0f172a; --text-secondary: #475569; --text-muted: #94a3b8; --accent: #0d9488; --accent-dark: #0f766e; --accent-light: #ccfbf1; --border: #e2e8f0; --font-display: 'Source Serif 4', Georgia, serif; --font-body: 'Inter', -apple-system, sans-serif; }
        html { scroll-behavior: smooth; } * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: var(--font-body); background: var(--bg-primary); color: var(--text-primary); line-height: 1.7; font-size: 16px; }
        header { position: fixed; top: 0; left: 0; right: 0; z-index: 100; background: rgba(255,255,255,0.95); backdrop-filter: blur(10px); border-bottom: 1px solid var(--border); }
        .header-inner { max-width: 1100px; margin: 0 auto; padding: 16px 24px; display: flex; justify-content: space-between; align-items: center; }
        .logo { font-family: var(--font-display); font-size: 22px; font-weight: 600; color: var(--text-primary); text-decoration: none; } .logo span { color: var(--accent); }
        nav { display: flex; gap: 32px; } nav a { color: var(--text-secondary); text-decoration: none; font-size: 14px; font-weight: 500; } nav a:hover { color: var(--accent); }
        .article-hero { padding: 120px 24px 48px; max-width: 720px; margin: 0 auto; }
        .breadcrumb { font-size: 13px; color: var(--text-muted); margin-bottom: 16px; } .breadcrumb a { color: var(--accent); text-decoration: none; }
        .article-hero h1 { font-family: var(--font-display); font-size: clamp(32px, 5vw, 44px); font-weight: 700; line-height: 1.2; margin-bottom: 16px; }
        .article-meta { display: flex; flex-wrap: wrap; gap: 16px; align-items: center; font-size: 13px; color: var(--text-muted); }
        .review-badge { display: inline-flex; align-items: center; gap: 6px; background: var(--accent-light); color: var(--accent-dark); padding: 4px 12px; border-radius: 100px; font-size: 12px; font-weight: 600; }
        main { max-width: 720px; margin: 0 auto; padding: 0 24px 64px; }
        .section { margin-bottom: 48px; } .section-label { font-size: 12px; font-weight: 600; color: var(--accent); text-transform: uppercase; letter-spacing: 1px; margin-bottom: 12px; }
        h2 { font-family: var(--font-display); font-size: 28px; font-weight: 700; margin-bottom: 16px; }
        h3 { font-family: var(--font-display); font-size: 22px; font-weight: 600; margin-bottom: 12px; margin-top: 32px; }
        main p { font-size: 17px; color: var(--text-secondary); margin-bottom: 16px; line-height: 1.8; }
        main ul, main ol { margin: 0 0 16px 24px; color: var(--text-secondary); font-size: 17px; line-height: 1.8; } main li { margin-bottom: 8px; }
        .info-box { background: var(--accent-light); border: 1px solid #99f6e4; border-left: 4px solid var(--accent); border-radius: 8px; padding: 20px; margin: 24px 0; }
        .info-box h4 { font-size: 16px; font-weight: 600; margin-bottom: 8px; color: var(--accent-dark); }
        .info-box p { font-size: 15px; color: var(--accent-dark); margin-bottom: 0; }
        .comparison-table { width: 100%; border-collapse: collapse; margin: 24px 0; border: 1px solid var(--border); border-radius: 8px; overflow: hidden; }
        .comparison-table thead { background: var(--bg-secondary); }
        .comparison-table th { padding: 12px 16px; text-align: left; font-size: 13px; font-weight: 600; border-bottom: 1px solid var(--border); }
        .comparison-table td { padding: 12px 16px; font-size: 14px; color: var(--text-secondary); border-bottom: 1px solid var(--border); }
        .comparison-table tr:last-child td { border-bottom: none; }
        .faq-section { background: var(--bg-secondary); border-radius: 12px; padding: 32px; margin: 48px 0; }
        .faq-section h2 { font-size: 24px; margin-bottom: 24px; }
        .faq-item { border-bottom: 1px solid var(--border); padding: 16px 0; } .faq-item:last-child { border-bottom: none; }
        .faq-question { font-weight: 600; font-size: 16px; margin-bottom: 8px; } .faq-answer { font-size: 15px; color: var(--text-secondary); line-height: 1.7; }
        .sources { margin-top: 48px; padding-top: 32px; border-top: 1px solid var(--border); }
        .sources h3 { font-size: 18px; margin-bottom: 16px; margin-top: 0; }
        .sources ol { font-size: 14px; color: var(--text-muted); line-height: 1.8; } .sources a { color: var(--accent); text-decoration: none; }
        .related-articles { margin-top: 48px; padding: 32px; background: var(--bg-secondary); border-radius: 12px; }
        .related-articles h3 { font-size: 18px; margin-bottom: 16px; margin-top: 0; }
        .related-articles a { display: block; color: var(--accent); text-decoration: none; font-size: 15px; margin-bottom: 8px; font-weight: 500; }
        footer { background: var(--bg-secondary); border-top: 1px solid var(--border); padding: 48px 24px; }
        .footer-inner { max-width: 1100px; margin: 0 auto; text-align: center; }
        .footer-inner p { font-size: 14px; color: var(--text-muted); margin-bottom: 8px; } .footer-inner a { color: var(--accent); text-decoration: none; }
        @media (max-width: 768px) { nav { display: none; } .article-hero { padding: 100px 16px 32px; } .article-hero h1 { font-size: 28px; } main { padding: 0 16px 48px; } .faq-section { padding: 20px; } .comparison-table th, .comparison-table td { padding: 8px 10px; font-size: 12px; } }
    </style>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="https://ozempic.md" class="logo">ozempic<span>.md</span></a>
            <nav>
                <a href="https://ozempic.md">Home</a>
                <a href="https://ozempic.md/how-ozempic-works">How It Works</a>
                <a href="https://ozempic.md/side-effects-long-term">Side Effects</a>
                <a href="https://ozempic.md/ozempic-cost">Cost</a>
            </nav>
        </div>
    </header>

    <div class="article-hero">
        <div class="breadcrumb"><a href="https://ozempic.md">Home</a> → Ozempic vs Mounjaro</div>
        <h1>Ozempic vs Mounjaro: Which Is Better for Weight Loss?</h1>
        <div class="article-meta">
            <span class="review-badge">✓ Medically reviewed by Dr. Agustin Arrieta, MD</span>
            <span>Last updated: February 2026</span>
        </div>
    </div>

    <main>
        <div class="section">
            <p>Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two most prescribed GLP-1-based medications for type 2 diabetes, and both produce significant weight loss. But they work differently, and the clinical data shows meaningful differences in outcomes.</p>
            <p>This comparison breaks down the head-to-head data, mechanism differences, cost, side effects, and practical considerations to help you and your doctor make the right choice.</p>
        </div>

        <div class="section">
            <div class="section-label">Quick Comparison</div>
            <h2>Ozempic vs Mounjaro at a Glance</h2>

            <table class="comparison-table">
                <thead>
                    <tr><th>Feature</th><th>Ozempic (Semaglutide)</th><th>Mounjaro (Tirzepatide)</th></tr>
                </thead>
                <tbody>
                    <tr><td><strong>Manufacturer</strong></td><td>Novo Nordisk</td><td>Eli Lilly</td></tr>
                    <tr><td><strong>Drug class</strong></td><td>GLP-1 receptor agonist</td><td>Dual GIP/GLP-1 receptor agonist</td></tr>
                    <tr><td><strong>FDA approvals</strong></td><td>Type 2 diabetes, CV risk reduction</td><td>Type 2 diabetes</td></tr>
                    <tr><td><strong>Frequency</strong></td><td>Once weekly (injection)</td><td>Once weekly (injection)</td></tr>
                    <tr><td><strong>Doses available</strong></td><td>0.25, 0.5, 1, 2 mg</td><td>2.5, 5, 7.5, 10, 12.5, 15 mg</td></tr>
                    <tr><td><strong>Avg. A1C reduction</strong></td><td>1.2–1.8%</td><td>1.9–2.5%</td></tr>
                    <tr><td><strong>Avg. weight loss (diabetes)</strong></td><td>12–14 lbs</td><td>15–25 lbs</td></tr>
                    <tr><td><strong>Retail cost (no insurance)</strong></td><td>~$900–1,000/month</td><td>~$1,000–1,100/month</td></tr>
                    <tr><td><strong>CV outcomes data</strong></td><td>Yes (SUSTAIN 6: 26% MACE reduction)</td><td>Pending (SURPASS-CVOT ongoing)</td></tr>
                    <tr><td><strong>Weight-loss formulation</strong></td><td>Wegovy (semaglutide 2.4 mg)</td><td>Zepbound (tirzepatide)</td></tr>
                    <tr><td><strong>Available since</strong></td><td>2017</td><td>2022</td></tr>
                </tbody>
            </table>
        </div>

        <div class="section">
            <div class="section-label">Mechanism</div>
            <h2>How They Work Differently</h2>

            <p>This is the fundamental distinction between the two drugs, and it likely explains the differences in clinical outcomes.</p>

            <h3>Ozempic: Single GLP-1 Agonist</h3>
            <p>Semaglutide activates the GLP-1 receptor only. This single-pathway approach stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through brain signaling. It is a proven, well-understood mechanism backed by decades of GLP-1 research.</p>

            <h3>Mounjaro: Dual GIP/GLP-1 Agonist</h3>
            <p>Tirzepatide is the first approved dual incretin agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone that:</p>
            <ul>
                <li>Enhances insulin secretion through a pathway complementary to GLP-1</li>
                <li>May improve fat tissue metabolism and insulin sensitivity</li>
                <li>Appears to have independent effects on appetite and weight regulation</li>
                <li>May enhance the GLP-1 pathway's effects through receptor cross-talk</li>
            </ul>

            <p>The dual mechanism creates a "1 + 1 = 3" effect — the combination of GIP and GLP-1 agonism appears to produce greater metabolic improvements than either pathway alone. This is the leading hypothesis for why Mounjaro shows superior weight loss and A1C reduction in clinical trials.</p>

            <div class="info-box">
                <h4>Why GIP Matters</h4>
                <p>Interestingly, GIP was initially studied as an antagonist (blocker) for obesity treatment. The discovery that GIP agonism — when combined with GLP-1 agonism — produces greater weight loss was unexpected and represents a paradigm shift in metabolic pharmacology.</p>
            </div>
        </div>

        <div class="section">
            <div class="section-label">Clinical Data</div>
            <h2>Head-to-Head Comparison: What the Trials Show</h2>

            <h3>Weight Loss</h3>
            <p>While there's limited direct head-to-head trial data, cross-trial comparisons and the SURPASS-2 study (which compared tirzepatide to semaglutide 1 mg) provide clear signals:</p>

            <table class="comparison-table">
                <thead>
                    <tr><th>Study</th><th>Drug / Dose</th><th>Avg. Weight Loss</th><th>Duration</th></tr>
                </thead>
                <tbody>
                    <tr><td>SUSTAIN 7</td><td>Semaglutide 0.5 mg</td><td>9.3 lbs (4.3 kg)</td><td>40 weeks</td></tr>
                    <tr><td>SUSTAIN 7</td><td>Semaglutide 1 mg</td><td>13.0 lbs (5.9 kg)</td><td>40 weeks</td></tr>
                    <tr><td>SURPASS-2</td><td>Semaglutide 1 mg (comparator)</td><td>12.5 lbs (5.7 kg)</td><td>40 weeks</td></tr>
                    <tr><td>SURPASS-2</td><td>Tirzepatide 5 mg</td><td>16.5 lbs (7.6 kg)</td><td>40 weeks</td></tr>
                    <tr><td>SURPASS-2</td><td>Tirzepatide 10 mg</td><td>21.4 lbs (9.8 kg)</td><td>40 weeks</td></tr>
                    <tr><td>SURPASS-2</td><td>Tirzepatide 15 mg</td><td>25.3 lbs (11.2 kg)</td><td>40 weeks</td></tr>
                </tbody>
            </table>
            <p style="font-size: 13px; color: var(--text-muted);">SURPASS-2 is the only head-to-head trial comparing tirzepatide directly to semaglutide 1 mg. All tirzepatide doses showed statistically superior weight loss.</p>

            <h3>A1C Reduction (Blood Sugar Control)</h3>
            <p>In SURPASS-2, tirzepatide showed superior A1C reduction compared to semaglutide 1 mg at all three doses:</p>
            <ul>
                <li><strong>Tirzepatide 5 mg:</strong> -2.01% (vs -1.86% for semaglutide 1 mg)</li>
                <li><strong>Tirzepatide 10 mg:</strong> -2.24%</li>
                <li><strong>Tirzepatide 15 mg:</strong> -2.30%</li>
            </ul>
            <p>The differences were statistically significant for the 10 mg and 15 mg doses but not for the 5 mg dose, suggesting that tirzepatide's advantage becomes more pronounced at higher doses.</p>

            <h3>Cardiovascular Outcomes</h3>
            <p>Ozempic has a clear advantage here — <strong>proven cardiovascular benefit</strong>. The SUSTAIN 6 trial demonstrated a 26% reduction in major adverse cardiovascular events (MACE), and Ozempic carries an FDA-approved cardiovascular indication.</p>
            <p>Mounjaro does not yet have cardiovascular outcomes data. The SURPASS-CVOT trial is ongoing, with results expected in 2026. Until this data is available, Ozempic remains the preferred choice for patients where cardiovascular risk reduction is a primary treatment goal.</p>
        </div>

        <div class="section">
            <div class="section-label">Side Effects</div>
            <h2>Side Effect Comparison</h2>

            <table class="comparison-table">
                <thead>
                    <tr><th>Side Effect</th><th>Ozempic</th><th>Mounjaro</th></tr>
                </thead>
                <tbody>
                    <tr><td>Nausea</td><td>15–20%</td><td>12–18%</td></tr>
                    <tr><td>Diarrhea</td><td>8–9%</td><td>12–17%</td></tr>
                    <tr><td>Vomiting</td><td>5–9%</td><td>5–9%</td></tr>
                    <tr><td>Constipation</td><td>3–5%</td><td>6–8%</td></tr>
                    <tr><td>Decreased appetite</td><td>5–9%</td><td>5–11%</td></tr>
                    <tr><td>Injection site reactions</td><td>0.2%</td><td>3–5%</td></tr>
                    <tr><td>Discontinuation rate (GI)</td><td>4–5%</td><td>4–7%</td></tr>
                </tbody>
            </table>

            <p>The overall GI side effect profiles are similar. Both cause nausea, diarrhea, and vomiting most commonly during dose escalation. Mounjaro has slightly higher rates of diarrhea, constipation, and injection site reactions. Both medications use gradual dose titration to minimize side effects.</p>

            <p>Both carry the same FDA boxed warning for thyroid C-cell tumors based on rodent studies, and both are contraindicated in patients with MTC or MEN 2 history.</p>
        </div>

        <div class="section">
            <div class="section-label">Cost</div>
            <h2>What You'll Pay</h2>

            <table class="comparison-table">
                <thead>
                    <tr><th>Cost Factor</th><th>Ozempic</th><th>Mounjaro</th></tr>
                </thead>
                <tbody>
                    <tr><td>Retail price (no insurance)</td><td>$900–1,000/month</td><td>$1,000–1,100/month</td></tr>
                    <tr><td>Manufacturer savings card</td><td>As low as $25/month (eligible patients)</td><td>As low as $25/month (eligible patients)</td></tr>
                    <tr><td>Medicare Part D</td><td>Covered for diabetes (varies by plan)</td><td>Covered for diabetes (varies by plan)</td></tr>
                    <tr><td>Insurance formulary position</td><td>Widely covered (preferred in many plans)</td><td>Increasingly covered (newer, less formulary placement)</td></tr>
                </tbody>
            </table>

            <p>Ozempic has a slight edge in insurance coverage simply because it's been on the market longer (since 2017 vs 2022 for Mounjaro) and has more formulary placements. However, this gap is closing rapidly as payers add Mounjaro to their formularies.</p>
            <p>For weight-loss-specific formulations, Wegovy (semaglutide) and Zepbound (tirzepatide) are similarly priced at approximately $1,300-$1,400/month without insurance.</p>
        </div>

        <div class="section">
            <div class="section-label">Decision Framework</div>
            <h2>Which Should You Choose?</h2>

            <p><strong>Mounjaro may be better if:</strong></p>
            <ul>
                <li>Weight loss is your primary goal (greater average weight loss in trials)</li>
                <li>You need maximum A1C reduction</li>
                <li>You've plateaued on Ozempic or another GLP-1 agonist</li>
                <li>Your insurance covers it equally</li>
            </ul>

            <p><strong>Ozempic may be better if:</strong></p>
            <ul>
                <li>Cardiovascular risk reduction is a treatment priority (proven MACE reduction)</li>
                <li>You want a longer safety track record (on market since 2017)</li>
                <li>Your insurance has better coverage for Ozempic</li>
                <li>You prefer a medication with more dosing flexibility on the lower end</li>
            </ul>

            <p><strong>Either medication is a reasonable choice if:</strong></p>
            <ul>
                <li>You have type 2 diabetes and need better blood sugar control</li>
                <li>You want a once-weekly injectable with a proven safety profile</li>
                <li>You're willing to manage GI side effects during dose escalation</li>
            </ul>

            <div class="info-box">
                <h4>Bottom Line</h4>
                <p>If the data were the only factor, Mounjaro's dual mechanism and superior weight loss/A1C data would make it the default choice for most patients. But in practice, insurance coverage, cardiovascular history, and individual response all matter. Many patients do well on either medication. Discuss both options with your healthcare provider.</p>
            </div>
        </div>

        <div class="faq-section">
            <h2>Frequently Asked Questions</h2>

            <div class="faq-item">
                <div class="faq-question">Is Mounjaro better than Ozempic for weight loss?</div>
                <div class="faq-answer">Clinical trials suggest Mounjaro produces greater average weight loss. In SURPASS-2, tirzepatide 15 mg produced ~25 lbs weight loss vs ~12.5 lbs with semaglutide 1 mg over 40 weeks. However, individual responses vary, and the best medication depends on your overall health profile.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">What is the difference between Ozempic and Mounjaro?</div>
                <div class="faq-answer">The key difference is mechanism: Ozempic targets only GLP-1 receptors, while Mounjaro targets both GLP-1 and GIP receptors (dual agonist). This dual mechanism appears to produce greater A1C reduction and weight loss.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Which has fewer side effects, Ozempic or Mounjaro?</div>
                <div class="faq-answer">Both have similar GI side effect profiles. Nausea rates are comparable (~15-20% for Ozempic, ~12-18% for Mounjaro). Mounjaro has slightly higher diarrhea and injection site reaction rates. Overall discontinuation rates due to side effects are similar at 4-7%.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Is Ozempic or Mounjaro cheaper?</div>
                <div class="faq-answer">Both are similarly priced: Ozempic ~$900-1,000/month and Mounjaro ~$1,000-1,100/month without insurance. Both offer savings cards that may reduce copays to $25/month. Ozempic currently has broader insurance formulary coverage.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Can I switch from Ozempic to Mounjaro?</div>
                <div class="faq-answer">Yes, under medical supervision. Your doctor will determine the appropriate starting dose. No washout period is required. Common reasons for switching include weight loss plateau or desire for greater A1C reduction.</div>
            </div>
            <div class="faq-item">
                <div class="faq-question">Does Mounjaro have a cardiovascular benefit like Ozempic?</div>
                <div class="faq-answer">Ozempic has proven cardiovascular benefit (SUSTAIN 6: 26% MACE reduction). Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing with results expected in 2026. Until then, Ozempic is preferred when CV risk reduction is a primary goal.</div>
            </div>
        </div>

        <div class="sources">
            <h3>Sources</h3>
            <ol>
                <li>Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." <em>N Engl J Med.</em> 2021;385(6):503-515. <a href="https://doi.org/10.1056/NEJMoa2107519">doi:10.1056/NEJMoa2107519</a> (SURPASS-2)</li>
                <li>Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." <em>N Engl J Med.</em> 2016;375(19):1834-1844. <a href="https://doi.org/10.1056/NEJMoa1607141">doi:10.1056/NEJMoa1607141</a></li>
                <li>Rosenstock J, et al. "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)." <em>Lancet.</em> 2021;398(10295):143-155.</li>
                <li>FDA. "Ozempic (semaglutide) Prescribing Information." <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf">FDA Label</a></li>
                <li>FDA. "Mounjaro (tirzepatide) Prescribing Information." <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf">FDA Label</a></li>
                <li>Del Prato S, et al. "Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4)." <em>Lancet.</em> 2021;398(10313):1811-1824.</li>
            </ol>
        </div>

        <div class="related-articles">
            <h3>Related Articles</h3>
            <a href="https://ozempic.md/ozempic-vs-wegovy">Ozempic vs Wegovy: Same Drug, Different Uses →</a>
            <a href="https://ozempic.md/how-ozempic-works">How Ozempic Works for Weight Loss: Mechanism Explained →</a>
            <a href="https://ozempic.md/ozempic-cost">How Much Does Ozempic Cost? →</a>
            <a href="https://ozempic.md/side-effects-long-term">Ozempic Side Effects: What to Expect →</a>
            <a href="https://ozempic.md/what-happens-when-you-stop">What Happens When You Stop Taking Ozempic →</a>
        </div>
    </main>

    <footer>
        <div class="footer-inner">
            <p><a href="https://ozempic.md" class="logo" style="font-size:18px;">ozempic<span>.md</span></a></p>
            <p>Evidence-based information about Ozempic (semaglutide). Not medical advice. Always consult your healthcare provider.</p>
            <p>Part of the <a href="https://thrive.md">thrive.md</a> network. © 2026</p>
        </div>
    </footer>
</body>
</html>
